Seegene has announced plans to launch its new Covid-19 PCR test, Allplex SARS-CoV-2 Fast PCR Assay, later this month.

The new test targets the E, RdRP and N Covid-19 genes, in order to detect the disease regardless of variants, and provides results in 60 minutes.

It is expected to reduce the total turnaround time for mass testing and triple the testing capacity for laboratories and hospitals while eliminating the need for additional instruments.

Seegene stated that the new Covid-19 PCR test’s turnaround time was reduced due to the use of a new enzyme and its innovative extraction-free method.

The enzyme developed by the company reduces PCR process times by half while the extraction-free method removes the sample preparation extraction needed for PCR-based tests.

This helps reduce the total turnaround time for each result, as well as the amount of hands-on processing time.

Seegene chief sales and marketing officer Ho Yi said: “This assay will be the optimised choice for laboratories and hospitals where they conduct large-scale testing as it helps them immediately expand the testing capacity with lessening the burden of healthcare workers.

“For the time being, we plan to target large-scale testing markets in more than 60 countries all across the globe.

“The next step in our journey is to develop a new gold-standard molecular diagnostic assay that fully matches the speed of antigen tests with the same degree of accuracy as PCR test.”

Clinical research conducted in seven countries by 17 laboratories demonstrated that the new Allplex SARS-CoV-2 Fast PCR assay had the same or better accuracy for the detection of Covid-19 compared to other available diagnostic tests.

In a previous development, Seegene received authorisation from Health Canada for its Allplex SARS CoV-2 FluA/FluB/RSV Assay.